Seismed Instruments has been engaged in the development of noninvasive diagnostic cardiology instrumentation using seismic technology to evaluate mechanical heart function, a procedure known as seismocardiography
The company's initial strategy was the development of the SCG-2000 seismocardiograph, which applies the company's seismocardiography
(SCG) technology to the evaluation of cardiac function and to the detection of coronary artery disease for the stress testing market.
MINNEAPOLIS, March 4 /PRNewswire/ -- Seismed Instruments (NASDAQ: SEIS) announces the publication of a Multicenter Clinical Study on stress seismocardiography
This also coincides with the March publication of a national multicenter study on stress seismocardiography
The company's primary focus in product development is on the completion of the SE-4000, a comprehensive 12-lead electrocardiography (EKG) stress system which will incorporate the stress seismocardiography
(SCG) test giving the instrument a significant competitive feature.
The results of the Multicenter Study confirm the findings of the first major clinical study on exercise seismocardiography
(SCG) which was conducted at the Minneapolis Heart Institute on over 1,200 patients and will soon be published in the American Journal of Noninvasive Cardiology.